ALKEM

Alkem continues to perform well in domestic formulations, supported by strong chronic therapy brands. US business remains stable, though not a major growth driver. Margins remain healthy, aided by operational efficiency. With limited regulatory overhang and strong India focus, Alkem is a steady pharma compounder suitable for risk-averse investors.